The U.S. Food and Drug Administration (FDA) has cleared RapidAI's Rapid RV/LV, a program that calculates heart metrics associated with pulmonary embolism.
The software assesses the ratio between the right ventricle and the left ventricle, a key indicator of pulmonary embolism severity. Key benefits of Rapid RV/LV include identifying patients with possible right heart strain, reducing time to diagnosis, and reducing variability in RV/LV measurements, according to the company.
